Cancer Vaccines: Abzena and Genentech Go Under the Microscope in Exclusive New Interviews
SMi Group add two new Q&A’s to the cancer vaccines interview series with Abzena and Genentech in the run up to their keynote addresses at Cancer Vaccines 2016
London, United Kingdom, August 12, 2016 --(PR.com)-- SMi's 5th annual Cancer Vaccines conference will return to London this autumn to showcase the latest advances in clinical breakthroughs. In the run up to the industry congress taking place on 21st and 22nd September, SMi Group caught up Abzena and Genentech to discuss current medical developments and their upcoming talks.
Personalised therapy came up as an area showing most potential when asked about research demonstrating promise.
Genetech’s Medical Director, Daejin Abidoye said:
“Achieving a sustained antitumor immune response will depend largely on understanding patterns and mechanism of resistance. We are actively investigating this at Roche-Genentech. Understanding how these agents affect the cancer immunity cycle and how these pathways are altered in disease progression will be key in developing strategies to overcome resistance, enabling a sustained antitumor immune response. Personalizing immunotherapy is necessary to optimize selection of combination therapy to improve response rates and salvage disease progression.”
Mark Fogg, Head of Immunology, Abzena commented:
“Clearly the combination of cancer vaccines with the successful checkpoint treatment strategies is the most active area of research. There is considerable activity in characterising and profiling expression of neo-antigens which offers the potential to develop stratified or personalised vaccine design. Combining this with more targeted ways to better engage the immune stem through enrolling dendritic cells to present optimally selected antigens/peptides is a very exciting prospect.”
The full interviews are available to read in the event download centre at: www.cancervaccinesevent.com/prcom
5th Annual Cancer Vaccines Conference
21st-22nd September 2016
Holiday Inn Kensington Forum, London, UK
www.cancervaccinesevent.com/prcom
Proudly Sponsored by: Abzena and Northwest Biotherapeutics
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.cancervaccinesevent.com/prcom or contact Matthew Apps on
Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Personalised therapy came up as an area showing most potential when asked about research demonstrating promise.
Genetech’s Medical Director, Daejin Abidoye said:
“Achieving a sustained antitumor immune response will depend largely on understanding patterns and mechanism of resistance. We are actively investigating this at Roche-Genentech. Understanding how these agents affect the cancer immunity cycle and how these pathways are altered in disease progression will be key in developing strategies to overcome resistance, enabling a sustained antitumor immune response. Personalizing immunotherapy is necessary to optimize selection of combination therapy to improve response rates and salvage disease progression.”
Mark Fogg, Head of Immunology, Abzena commented:
“Clearly the combination of cancer vaccines with the successful checkpoint treatment strategies is the most active area of research. There is considerable activity in characterising and profiling expression of neo-antigens which offers the potential to develop stratified or personalised vaccine design. Combining this with more targeted ways to better engage the immune stem through enrolling dendritic cells to present optimally selected antigens/peptides is a very exciting prospect.”
The full interviews are available to read in the event download centre at: www.cancervaccinesevent.com/prcom
5th Annual Cancer Vaccines Conference
21st-22nd September 2016
Holiday Inn Kensington Forum, London, UK
www.cancervaccinesevent.com/prcom
Proudly Sponsored by: Abzena and Northwest Biotherapeutics
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit www.cancervaccinesevent.com/prcom or contact Matthew Apps on
Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 (0)20 7827 6093
http://www.cancervaccinesevent.com/prcom
Teri Arri
+44 (0)20 7827 6093
http://www.cancervaccinesevent.com/prcom
Contact
Categories